Maciej Zarębiński

Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction

C. Michael Gibson, Serge Korjian, Pierluigi Tricoci et al. · Circulation · 2016 · 180 citations · Full text

A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction

Sunil V. Rao, Bodo Kirsch, Deepak L. Bhatt et al. · Circulation · 2022 · 142 citations · Full text

Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction

C. Michael Gibson, Serge Korjian, Pierluigi Tricoci et al. · American Heart Journal · 2016 · 32 citations

Thrombosis, Apo-i Event Reduction, Cardiovascular Disease +12

Ticagrelor-Related Severe Dyspnoea: Mechanisms, Characteristic Features, Differential Diagnosis and Treatment

Alicja Krakowiak, Jakub Kuleta, Iwona Plech et al. · Clinical Medicine Insights Case Reports · 2020 · 16 citations · Full text

Heart Failure, Pathology, Pharmacotherapy +17

A Randomized, double-blind, dose ranging clinical trial of intravenous FDY-5301 in acute STEMI patients undergoing primary PCI

David Adlam, Maciej Zarębiński, Neal Uren et al. · International Journal of Cardiology · 2021 · 16 citations · Full text

Thrombosis, Primary Pci, Hematology +6